Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia

Bone Marrow Transplantation

Volumn 23, Issue 12, 1999, Pages 1303-1308

  Clark, R E ^a,b   Grzybowski, J ^a   Broughton, C M ^a   Pender, N T ^a   Spiller, D G ^a   Brammer, C G ^a   Giles, R V ^a   Tidd, D M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antisense oligodeoxyribonucleotides; BCR ABL; Blood and marrow transplantation; Chronic myeloid leukaemia; Streptolysin O

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; BUSULFAN; CD34 ANTIGEN; MESSENGER RNA; STREPTOLYSIN O;

ADULT; ARTICLE; BLAST TRANSFORMATION; BONE MARROW PURGING; CASE REPORT; CELL SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLONY FORMING UNIT GM; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPHIL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RELAPSE;

EID: 0033516278     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701801     Document Type: Article

References (23)

1. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol 1994; 86: 76-81.
2. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
3. Carella AM, Gaozza E, Raffo MR et al. Therapy of acute phase chronic myelogenous leukaemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 5: 517-521.
4. Chalmers EA, Franklin IM, Kelsey SM et al. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilisation of Philadelphia negative peripheral blood stem cells. Br J Haematol 1997; 96: 627-634.
5. Carella AM, Frassoni F, Negrin RS. Autografting in chronic myelogenous leukaemia: new questions. Leukemia 1995; 9: 365-369.
6. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukaemia. Blood 1997; 89: 2623-2634.
7. Kantarjian HM, O, Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
8. Giles RV, Spiller DG, Green JA et al. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 1995; 86: 744-754.
9. Spiller DG, Giles RV, Grzybowski J et al. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukaemia cells: a comparison of streptolysin-O permeabilisation, electroporation and lipophilic conjugation. Blood 1998; 91: 4738-4746.
10. Broughton CM, Spiller DG, Pender N et al. Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients. Leukemia 1997; 11: 1435-1441.
11. Broughton CM, Sherrington P, Pender N et al. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. Genes Chromosomes Cancer 1997; 18: 292-298.
12. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxyribonucleotides through reversible permeabilisation of human leukaemia cells with Streptolysin O. Antisense Res Dev 1995; 5: 13-21.
13. Kirkland MA, O'Brien SG, Goldman JM. Antisense therapeutics in haematological malignacies. Br J Haematol 1994; 87: 447-452.
14. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.
15. Gewirtz AM, Luger S, Sokol D et al. Oligodeoxynucleotide therapeutics for human myelogenous leukaemia: interim results. Blood 1996; 88 (Suppl. 1): 270a.
16. de Fabritiis P, Petti MC, Montefusco E et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156-3162.
17. Giles RV, Grzybowski J, Spiller DG, Tidd DM. Enhanced antisense effects resulting from an improved streptolysin-O protocol for oligodeoxynucleotide delivery into human leukaemia cells. Nucleosides Nucleotides 1997; 16: 1155-1163.
18. Mahon FX, Ripoche J, Pigeonnier V et al. Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted to the B2A2 junction. Exp Hematol 1995; 23: 1606-1611.
19. + cells arising from hematopoietic progenitors in chronic myeloid leukaemia. Blood 1994; 83: 1744-1749.
20. Bedi A, Zehnbauer BA, Collector MI et al. BCR-ABL gene re-arrangement and expression of primitive haematopoietic progenitors in chronic myeloid leukaemia. Blood 1994; 81: 2898-2902.
21. Spiller DG, Giles RV, Broughton CM et al. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analogue mediated biological responses. Antisense Nucleic Acid Drug Dev 1998; 8: 281-283.
22. Verfaillie CM, Bhatia R, Miller W et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukaemia patients. Blood 1996; 87: 4770-4779.
23. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contibute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.